Wedbush Reiterates Outperform on Verona Pharma, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Liana Moussatos has reiterated an Outperform rating on Verona Pharma (NASDAQ:VRNA) and maintained a $30 price target.
June 28, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verona Pharma's stock rating has been reiterated as Outperform by Wedbush, with a maintained price target of $30.
The reiteration of an Outperform rating by a reputable analyst like Liana Moussatos from Wedbush is a positive signal for Verona Pharma. The maintained price target of $30 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100